Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV) (LHIV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00933595|
Recruitment Status : Completed
First Posted : July 7, 2009
Last Update Posted : September 1, 2016
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Complications HIV Infections||Other: Smoking Cessation||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV)|
|Study Start Date :||September 2007|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||November 2013|
Experimental: Smoking Cessation
The overall smoking cessation rate for the intervention is 18.8 at 3 months, 13.1 at 6 months and 10.0 at 12 months.
Other: Smoking Cessation
A Motivational Interview session (~40-50 minutes) will be delivered by a trained nurse coordinator.
Treatment with varenicline (1 mg daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12)or nicotine replacement therapy (21 mg of a skin patch + nicotine gum 4 mg ad lib added for breakthrough craving up to 20 pieces/day.
- To develop and evaluate a specialized smoking cessation intervention for the treatment of nicotine dependence in HIV-seropositive smokers. [ Time Frame: 5 years ]
- To examine the effects of smoking cessation on the course of lung function decline, the prevalence of respiratory symptoms and the occurrence/progression of emphysema in a cohort of HIV-seropositive individuals. [ Time Frame: 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00933595
|United States, Ohio|
|Ohio State University|
|Columbus, Ohio, United States, 43210|
|Study Director:||Hannah Peavy, MD||NHLBI Project Officer|